- Status Withdrawn
- Type New application
- Pre-PASC consultation Not applicable
- Pre-MSAC consultation Closed
- Outcome Not applicable
Application details
Reason for application
MSAC-PBAC co-dependent submission
Service or technology in this application
The proposed services are two testing options, either of which could be used to detect the presence of amyloid beta (Aß) pathology in patients with Alzheimer’s Disease.
The two tests are Aß positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) AD biomarker testing. A positive test result is to be used to determine patient eligibility to the drug treatment, lecanemab. A separate application will be made to the Pharmaceutical Benefits Advisory Committee for subsidy of the drug.
Type: Investigative technology
Medical condition this application addresses
Alzheimer’s Disease is a progressive, neurodegenerative disorder, characterized by an unrelenting decline in cognition and behavioural disturbances, that result in the person’s inability to perform usual daily living activities.
The pathophysiology is related to the injury and death of neurons, initiating in the hippocampus brain region that is involved with memory and learning, followed by gradual atrophy of the entire brain.
Early symptoms include difficulty with recent memories, apathy, and depression. Later symptoms include impaired communication, disorientation, confusion, difficulty speaking, swallowing and walking.
Application documents
Application form
Consultation survey
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
Consultation survey and deadlines
- PASC consultation: Bypassing PASC
- MSAC consultation: Closed Friday 14 June 2024
Meetings to consider this application
- PASC meeting: Bypassing PASC
- ESC meeting: 13–14 June 2024
- MSAC meeting: -